Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Pain Management

The US Food and Drug Administration (FDA) has approved a short-acting formulation of oxycodone (Oxecta, Pfizer) that uses “Aversion” technology to stop potential abusers from crushing, chewing, snorting, or injecting the drug. Oral abuse remains possible. In addition, Pfizer acknowledged that the potential to abuse the drug through all routes is feasible.

 

The drug is indicated for acute and chronic moderate-to-severe pain.


Results 1 - 1 of 1